Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)
The purpose of this study is to evaluate the safety and efficacy of the NanoKnife LEDC System for the treatment of early-stage hepatocellular carcinoma (HCC).
Carcinoma, Hepatocellular
DEVICE: Ablation with the NanoKnife Low Energy Direct Current (LEDC) System
Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging., 30 days (+/- 3 days) post treatment
Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria., Immediately post treatment to 2 years post treatment
The purpose of this study is to evaluate the safety and efficacy of the NanoKnife LEDC System for the treatment of early-stage hepatocellular carcinoma (HCC).